Invidior Shares Slammed After Bup Generics Court Ruling
11/21/2018 -ATIN- Expecting cutthroat competition in the buprenorphine pharmaceutical marketplace, a more than $1B blockbuster pharma sector, investors pummeled the shares of the former Reckitt Benckiser, now called Invidior, after a federal court lifted an injunction against the introduction of buprenorphine generic drugs.

Invidior, the developer of buprenorphine, which is the company's sole pharma product, has long kept prices of the drug high, extending and milking patents by tweaking the formula - adding naloxone to make Suboxone and now offering monthly injection Sublocade - and by going to court to keep generics competition off the market.

The importance to Invidior of the legal fight, which has played out in New Jersey federal court, became abundantly clear this week after a federal court lifted a preliminary injunction against Indian generics manufacturer Dr. Reddy's Laboratories, one of three companies planning to introduce generic buprenorphine. Investors have driven Invidior shares more than 60 percent lower after the ruling.

Dr.Reddy's Laboratories plans to introduce generic Suboxone, good news for consumers who have paid cash pay prices of hundreds of dollars a month for their daily maintenance dose of Suboxone. Suboxone is also used extensively to taper opiate addicts while detoxing.

This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Comments (0)Add Comment

Write comment
smaller | bigger


Recent Print Issue: Sept 2015 | Subscribe Now!

Special Report
Austin's MAP Looking to Future
andValue-Based Compensation
Growth Through Licensing

On the Cover: Jacob Levinson
Founder, CEO MAP

Click here to read the digital
print edition of TM.

Follow Treatment Magazine on Twitter!
Become a fan of Treatment Magazine on Facebook!